Glycogen phosphorylase isoenzyme BB (GPBB) is a marker of acute coronary syndromes. Pre-eclampsia (PE) and coronary syndrome share several aetiological and pathophysiological features. GPBB levels have previously been found to be elevated in pregnancy and preterm PE.
We conducted 6 case-control studies within the SCOPE Ireland cohort to investigate whether plasma GPBB levels are altered at time of disease presentation and to examine if GPBB has any power as a predictive biomarker at earlier gestations. Methods Blood samples were taken at time of presentation with PE (n = 25) and SGA (n = 23) and also at 15 and 20 weeks gestation for PE with no SGA (n = 33), PE and SGA (n = 18), SGA no PE with gestational hypertension (GH) (n = 25) and no GH (n = 25). All were matched to uncomplicated pregnancy controls. GPBB plasma concentration was measured with GPBB-ELISA kits (Diagenics, Germany).
The plasma GPBB concentration at disease presentation with PE and SGA was significantly higher than in normal uncomplicated pregnancies. There was no difference in plasma GPBB levels at 15 or 20 weeks’ gestation in women who subsequently developed PE or SGA compared with controls.
Plasma GPBB is increased at time of presentation with PE and SGA suggesting that plasma GPBB is a biomarker of uteroplacental insufficiency. However, we found no evidence to support its use as an early pregnancy biomarker as it was not significantly elevated at 15 or 20 weeks’ gestation.